These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34013205)

  • 1. H3K27M and
    Osada Y; Saito R; Shibahara I; Sasaki K; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
    Neurooncol Adv; 2021; 3(1):vdab038. PubMed ID: 34013205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
    Vuong HG; Ngo TNM; Le HT; Dunn IF
    J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
    Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
    Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
    Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW
    Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines.
    Bai H; Bai S; Li X; Zhang Y; Li Y; He F; Cheng W
    Biomed Res Int; 2021; 2021():3271395. PubMed ID: 34159191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas.
    Vuong HG; Ngo TNM; Le HT; Jea A; Hrachova M; Battiste J; McNall-Knapp R; Dunn IF
    Front Oncol; 2022; 12():858148. PubMed ID: 35371982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Molecular Characteristics of Thalamic Gliomas: Retrospective Report of 26 Cases.
    Liu Y; Zhang Y; Hua W; Li Z; Wu B; Liu W
    World Neurosurg; 2019 Jun; 126():e1169-e1182. PubMed ID: 30885860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
    Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
    Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult IDH wild-type lower-grade gliomas should be further stratified.
    Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
    Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
    Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
    Front Oncol; 2020; 10():795. PubMed ID: 32582540
    [No Abstract]   [Full Text] [Related]  

  • 13. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
    Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Picca A; Berzero G; Bielle F; Touat M; Savatovsky J; Polivka M; Trisolini E; Meunier S; Schmitt Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Di Stefano AL; Sanson M
    Neurology; 2018 Jun; 90(23):e2086-e2094. PubMed ID: 29728520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of
    Lee Y; Park CK; Park SH
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.
    Grimaldi S; Harlay V; Appay R; Bequet C; Petrirena G; Campello C; Barrié M; Autran D; Boissonneau S; Graillon T; Figarella-Branger D; Nanni I; Chinot O; Tabouret E
    J Neurooncol; 2022 Feb; 156(3):615-623. PubMed ID: 34994963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
    Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Surgery in IDH-Wild-Type Lower-Grade Gliomas: Threshold at a High Extent of Resection Should be Pursued.
    Wang P; Luo C; Hong PJ; Rui WT; Wu S
    Neurosurgery; 2021 May; 88(6):1136-1144. PubMed ID: 33647953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.